Cooley advised the initial purchasers on Global Blood Therapeutics’ Rule 144A offering of $345 million aggregate principal amount of 1.875% Convertible Senior Notes due 2028.  In connection with the offering, GBT entered into capped call transactions. Goldman Sachs & Co. and Jefferies acted as joint book-running managers for the offering. Global Blood Therapeutics is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities.